Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock?

Vidac Pharma: New Investors or Even a Takeover?

Is the market completely off the mark with Vidac Pharma right now? This does indeed seem to be the case. After all, the stock has been trading sideways since early April. The biotech company’s market capitalization stands at just around EUR 33 million. Yet the announcement published on April 21 was significant. The announced review of strategic expansion into continental Europe could be far more than just a geographical expansion. Rather, there are indications that the oncology specialist could bring strategic investors on board or possibly even be acquired outright. This is because two major European incubators have signalled their interest in providing financial and operational support. The goal of such platforms is to attract high-growth biotech companies and bring together international investors and strategic partners. For Vidac Pharma, this could significantly facilitate access to capital and specialized infrastructure—particularly for future clinical trials and potential collaborations.

Furthermore, Vidac Pharma is in a crucial phase of clinical development. It is precisely at this stage that many larger pharmaceutical and biotech companies are looking for innovative targets to expand their pipelines. The planned spin-off of selected business units into a European spin-off structure could therefore also serve to make it significantly easier to establish equity investments or strategic partnerships. Particularly noteworthy is the focus on three of the most important European life sciences hubs with direct access to institutional investors, pharmaceutical companies, and specialized research institutions.

Vidac Pharma has already begun the search for an experienced executive to lead the planned European unit. CEO Max Herzberg emphasized that the initiative is part of the long-term growth strategy and is intended to improve access to capital, build partnerships, and scale operations.

Investors should not be unsettled by management’s recent share sales. This was announced well in advance, and Vidac benefits directly from it. The net proceeds will be made directly available to the company for financing, which is intended to accelerate development in the current year.

Novo Nordisk: Downward Trend Broken?

While Vidac’s stock is still working on a turnaround, Novo Nordisk appears to have succeeded in this regard. Since hitting a multi-year low of around EUR 30 in March, the Danish pharmaceutical giant’s stock has gained nearly 30%. With a price of EUR 39, the long-term downward trend appears to be slowly breaking. Recently, two announcements have boosted shareholder sentiment.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive recommendation for the approval of the daily Wegovy pill containing 25 mg of oral semaglutide in the EU. This could make Wegovy the first orally available GLP-1 therapy for weight management in Europe. The recommendation also includes data from the SELECT study, which shows that Wegovy can reduce the risk of serious cardiovascular events such as heart attack or stroke. According to its own statements, Novo Nordisk plans to launch the tablet form outside the US in initial markets starting in the second half of 2026.

The recommendation is based, among other things, on data from the OASIS study program. In the Phase 3b OASIS 4 study, patients with obesity or overweight and comorbidities achieved an average weight loss of 16.6% while taking 25 mg of oral semaglutide daily. About one-third of participants lost at least 20% of their body weight.

In addition, Novo Nordisk received a positive CHMP recommendation for Wegovy 7.2 mg in a single-use pen for the treatment of obesity in the European Union. According to the company, the higher semaglutide dosage, administered once weekly, is intended to make it easier for patients to use. Wegovy 7.2 mg is already available in the US under the name Wegovy HD and in the UK. The market launch in the EU is expected in the third quarter of 2026.

BioNTech: Analysts Sound the Alarm

While Vidac Pharma appears to be attracting strategic investors due to its oncology pipeline, BioNTech’s image has been severely tarnished. This is due to the surprising announcements that the founding couple will be leaving the company and that several locations in Germany will be closed. And how is the share price of Germany’s largest biotech company performing? Following the March slump to nearly EUR 68, a surprisingly rapid recovery to over EUR 94 followed within six weeks. However, another correction followed this, and the stock is currently trading just under EUR 80.

Analysts have recently been rather cautious in their comments. For example, Bernstein rated BioNTech stock “Market Perform” in its initial coverage. The price target is USD 96. Analysts thus currently see only limited upside potential. Notably, they are cautious in their comments regarding the development of the oncology pipeline.

The Bernstein analysis focuses in particular on the drug candidate Pumitamig from the PD-L1/VEGF class. According to analysts’ assessments, regulatory trials in this area carry an increased risk, as comparable drug approaches have often failed to demonstrate a statistically significant survival benefit. Accordingly, Bernstein is cautious in its assessment of the prospects for success of the ongoing development programs.

Furthermore, Bernstein’s risk-adjusted revenue estimates for the entire BioNTech pipeline are approximately 43% below current market consensus estimates. The experts consider expectations regarding market share and the technical probability of success for the PD-L1/VEGF programs to be particularly overly optimistic.

Buying BioNTech shares is not a priority at this time. The fact that the company is reducing capacity shortly before key trial data is released is not a good sign. In contrast, there are many factors pointing to rising prices at Vidac Pharma. The capital from the current insider sales will be made available to the company to accelerate growth. The stock market is currently greatly underestimating the interest shown by two major European incubators. Novo Nordisk appears to be breaking out of the downtrend that began in June 2024. However, this does not mean that the stock is cheap.

Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.